CORDIS
EU research results

CORDIS

English EN

SUrrogate markers for vascular Micro- and Macrovascular hard endpoints for Innovative diabetes Tools

Objective

Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can neither be prevented nor cured and the disease is associated with devastating chronic complications including coronary heart disease and stroke (macrovascular disease) as well as microvascular disorders leading to damage of the small blood vessels of the kidney (nephropathy), eye(retinopathy) and peripheral nerves (neuropathy). These complications impose an immense burden on the quality of life of the patients and account for more than 10% of health care costs in Europe. Therefore, novel means to prevent these devastating diabetic complications are needed. An important mean in this undertaking would be to develop tools which would make development of novel drugs for prevention of complications more feasible. The SUMMIT consortium brings together European key leaders in the field of diabetes research; scientists with a deep insight into genetics, biomarker discovery, development of novel imaging assays for assessing progression of complications, novel animal models for chronic diabetic complications, in silico models to predict development of complications and response to novel treatments. Given the track record of this unique group of scientists, it can be anticipated that they will not only during the 6-year period discover novel surrogate markers for vascular complications in diabetes, but also validate them in large representative cohorts aiming at prevention of the devastating complications.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Address

Binger Strasse
55218 Ingelheim

Germany

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Principal Investigator

Michael Mark (Dr.)

Administrative Contact

Megan Grether (Dr.)

Participants (25)

Sort alphabetically

Sort by EU Contribution

Expand all

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 4 413 330

BIOCOMPUTING PLATFORMS LTD OY

Finland

EU Contribution

€ 181 873

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 959 999

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 592 320

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy

EU Contribution

€ 184 999

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 234 998

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 2 500 280

THE UNIVERSITY OF EXETER

United Kingdom

EU Contribution

€ 465 999

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 162 618

SAMFUNDET FOLKHALSAN I SVENSKA FINLAND RF

Finland

EU Contribution

€ 450 258

TERVEYDEN JA HYVINVOINNIN LAITOS

Finland

EU Contribution

€ 228 946

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 1 246 775

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 701 629

UNIVERSITA DEGLI STUDI DI PADOVA

Italy

EU Contribution

€ 432 259

UNIVERSITA DEGLI STUDI DI PAVIA

Italy

EU Contribution

€ 292 499

UNIVERSITA DI PISA

Italy

EU Contribution

€ 455 404

UNIVERSITA CATTOLICA DEL SACRO CUORE

Italy

EU Contribution

€ 319 999

TURUN YLIOPISTO

Finland

EU Contribution

€ 370 625

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 309 749

Eli Lilly and Company Limited

United Kingdom

ASTRAZENECA AB

Sweden

F. HOFFMANN-LA ROCHE AG

Switzerland

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

EU Contribution

€ 150 000

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

PFIZER LIMITED

United Kingdom

Project information

Grant agreement ID: 115006

Status

Closed project

  • Start date

    1 November 2009

  • End date

    31 October 2015

Funded under:

FP7-JTI

  • Overall budget:

    € 33 620 196

  • EU contribution

    € 14 654 559

Coordinated by:

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Germany